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Objective: The aim of this systematic review was to assess the role of microsurgical reconstruction of the jaws in patients with bisphosphonate-related osteonecrosis, and 
biological complications after an observation period of at least 12 months. Material and 
methods: An electronic MEDLINE search supplemented by manual searching was conducted 
to identify studies reporting data of at least 12 months observation on the microsurgical 
reconstruction of the jaws in patients with bisphosphonate-related osteonecrosis. Results: 
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complications, with a success rate of 100% as no recurrence of osteonecrosis was registered. 
Conclusions: Microsurgical reconstruction of the jaws represents a valid treatment modality 
in patients with bisphosphonate-related osteonecrosis at 3rd stage of the disease.
Key words: Jaw diseases. Osteonecrosis. Bisphosphonates.
INTRODUCTION
Bisphosphonates are a new class of agents 
that have been increasingly recommended for 
use in patients with osteoporosis, Paget’s disease 
of bone, hypercalcemia of malignancy, osteolytic 
bone metastases, and osteolytic lesions of multiple 
myeloma (Figure 1)7,19
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to use of these medications, osteonecrosis of 
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of patients receiving these drugs in particular 
with intravenous administration. Based on a 
growing number of case reports and institutional 
reviews, bisphosphonate therapy may cause 
exposed and necrotic bone that is isolated to the 
jaw33,35. This complication could present after 
simple dentoalveolar surgery. The phenomenon 
of bisphosphonate-related osteonecrosis of jaws 
(BRONJ) was recognized a few years after their 
approval for use1	
!!"#
alerting the dental and medical communities of 
this complication28,37,38,43. Since brought to light in 
200323,47, well over 400 reports have been published 
concerning BRONJ. Despite this large volume of 
work, there are few data yet many hypotheses 
concerning the underlying pathophysiology. The 
physiologic effects of bisphosphonates on bone 
cells, osteoblasts, osteoclasts, and osteocytes, have 
recently been comprehensively reviewed39,40,41.
Osteoclasts represent the main cellular target 
of bisphosphonates46. $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#
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
repress osteoclast-mediated bone remodeling, 
through disruption of intracellular pathways. As 
remodeling is a vital role process in tissue renewal 
and bone healing, bisphosphonate-induced 
remodeling suppression causes relevant effects on 
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Primary  Indication Dose Route Relative 
Potency*
Etidronate Paget´s disease 300-750 mg daily for 6 months Oral 1
Tiludronate Paget´s disease 400 mg daily for 3 months Oral 50
Alendronate Osteoporosis 10 mg/day 
70 mg/week
Oral
Oral
1,000
Risedronate Osteoporosis 5 mg/day
35 mg/week
Oral
Oral
1,000
Ibandronate Osteoporosis 2.5 mg/day
150 mg/months
3 mg every 3 months
Oral
Oral
IV
1,000
Pamidronate Bone metastases 90 mg/3 weeks IV 1,000-5,000
Zoledronate Bone metastases 
Osteoporosis
4 mg/3 weeks
5 mg/year
IV
IV
10,000 +
Figure 1- Bisphosphonate preparations currently available in the United States (Abbreviation: Intravenous - IV, *Relative 
to etidronate)
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various tissue-level properties5,7,27,42.
The effects of bisphosphonates on osteocytes 
are less clear and more controversial. There is a 
high awareness on both direct and indirect effects, 
most of which are centered around the viability and 
integrity of these cells and their environment3,31,32.
Although systemic bone formation is reduced in 
the presence of bisphosphonates, this is primarily 
an indirect consequence of remodeling suppression 
and the coupling between resorption and formation. 
At the level of the individual basic multicellular 
unit, osteoblast activity appears unaffected9,13. 
Reports from small animal models suggest that 
bisphosphonates may suppress osteoblastic bone 
formation directly on those surfaces undergoing 
bone formation without prior resorption (i.e., 
formation modeling)21, although large animal 
models do not show a similar suppressive effect on 
periosteal surfaces4,26.
In addition, this evidence shows that osteoclasts 
and/or osteocytes are the main cells of interest 
for BRONJ pathogenesis. The basic premise 
of this hypothesis is that the jaw has a high 
remodeling rate and bisphosphonates suppress 
remodeling. There is no debate about the latter 
because this is the principal mechanism of action 
of bisphosphonates34,40,41. It is also clear that 
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envelope, is considerably higher in the jaw 
compared with other skeletal sites. The BRONJ 
hypothesis thus follows the idea that because 
remodeling is high in the jaw, and bisphosphonates 
suppress remodeling, this likely plays a role in the 
pathophysiology of BRONJ3,24.
Current information on the prevalence and 
incidence of BRONJ (and much rarer non-
bisphosphonate-associated events) is poor. These 
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well as incomplete reporting. Unfortunately, with 
current information sources, it is not possible to 
determine the prevalence or incidence rates16.
Strategies for the treatment of patients with, 
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Association of Oral and Maxillofacial Surgeons 
(AAOMS) Position Paper on Bisphosphonate-Related 
Osteonecrosis of the Jaws (Position Paper) and 
approved by the Board of Trustees in September 
20061. The Position Paper was developed by a 
task force appointed by the Board and composed 
of clinicians with extensive experience in treating 
these patients and basic science researchers. The 
knowledge base and experience in addressing 
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The task force was then called together again in 
August 2008 to review the 2006 recommendations, 
appraise the current published data, and revise 
the Position Paper and recommendations, where 
indicated. This update contains revisions to 
the diagnosis and staging and management 
strategies and highlights the status of basic science 
research35,36,38. The purpose of this updated Position 
Paper is to provide (Figure 2): 1. Perspectives on 
the risk of developing BRONJ and the risks and 
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decision-making of both the treating physician and 
the patient; 2. Guidance to clinicians regarding the 
differential diagnosis of BRONJ in patients with a 
history of treatment with intravenous (IV) or oral 
bisphosphonates; 3. Guidance to clinicians on 
possible BRONJ prevention measures and treatment 
of patients with BRONJ according to the presenting 
stage of the disease.
The aim of this systematic review was to assess 
the role of the microsurgical reconstruction of 
the jaws in patents affected by bisphosphonate-
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Figure 2- Staging and treatment strategies. [Ruggiero, et al.37 (2009)]
Abbreviations: bisphosphonate-related osteonecrosis of the jaw - BRONJ; intravenous - IV
*Exposed bone in maxillofacial region without resolution within 8-12 weeks in persons treated with bisphosphonate who 
have not undergone radiotherapy to jaws
†Regardless of disease stage, mobile segments of bone sequestrum should be removed without exposing uninvolved bone; 
extraction of symptomatic teeth within exposed, necrotic bone should be considered because it is unlikely that extraction 
will exacerbate established necrotic process
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oncologist in consultation with oral and maxillofacial surgeon and patient
§Discontinuation of oral bisphosphonate therapy in patients with BRONJ has been associated with gradual improvement in 
clinical disease. Discontinuation of oral bisphosphonates for 6-12 months may result in either spontaneous sequestration or 
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should be done in consultation with treating physician and patient
BRONJ Stage* Clinical description Treatment Strategies †‡§
At risk category No apparent necrotic bone in patients who 
have been treated with either oral or IV 
bisphosphonates
No treatment indicated. Patient education.
Stage 0 No clinical evidence of necrotic bone, but 
!	
Systemic management, including use of pain 
medication and antibiotics.
Stage 1 Exposed and necrotic bone in asymptomatic 
patients without evidence of infection
Antibacterial mouth rinse. Clinical follow-up on 
quarterly basis. Patient education and review of 
indications for continued bisphosphonate therapy. 
Stage 2 Exposed and necrotic bone associated with 
infectin as evidenced by pain and erythema in 
region of exposed bone with or without purulent 
drainage
Symptomatic treatment with oral antibiotics. Oral 
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debridement to relieve soft tissue irritation. 
Stage 3 Exposed and necrotic bone in patients with 
pain, infection, and one or more of the following: 
exposed and necrotic bone extending beyond 
the region of alveolar bone (inferior border and 
ramus in the mandible, maxillary sinus and 
zygoma in the maxilla), resulting in pathologic 
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communication, or osteolysis extending to the 
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Antibacterial mouth rinse. Antibiotic therapy and 
pain control. Surgical debridement/resection for 
longer term palliation of infection and pain.
SACCO R, SACCO G, ACOCELLA A, SALE S, SACCO N, BALDONI E
related osteonecrosis (Figure 3), highlighting the 
clinical effectiveness at short- and long-term using 
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biological complications after an observation period 
of at least 12 months in the cases of BRONJ at 
the 3rd stage (as per Position Paper of American 
Association of Oral and Maxillofacial Surgeons 
-AAOMS).
MATERIAL AND METHODS
Search strategy and inclusion criteria
A systematic review of the English literature 
was conducted for selected articles published from 
January 1976 to June 2009.
Searching was performed using an full-text 
electronic journal database (PubMed). The 
following key word combinations were applied: 
jaw osteonecrosis, osteonecrosis bisphosphonate, 
bisphosphonate-related osteonecrosis, microsurgical 
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full-text articles and related reviews, selected 
from the electronic search, were also performed. 
Furthermore, manual searching was conducted in 
the following journals for the considered period: 
American Journal Medicine, Bone, British Journal of 
Oral and Maxillofacial Surgery, Clinical Oral Implants 
Related Research, Journal of Periodontology, Journal 
of Oral and Maxillofacial Surgery, Journal of Oral 
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Figure 3- Lateral view of the right leg. Note the proximity of the common peroneal nerve to the proximal osteotomy, according 
to Anthony and Foster6 (1996)
Figure 4- Search strategy
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Pathology and Medicine, Journal of Prosthetic 
Dentistry, Oral Disease, Oral Oncology, Oral Surgery, 
Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontics, Quintessence International and The 
Laryngoscope.
From this extensive search, it was obvious that 
there were no randomized controlled clinical trials 
(RCTs) available, prospective or retrospective 
studies. In the absence of RCTs, prospective or 
retrospective studies, this systematic review was 
based on clinical cases (case series, case report):
- that had a mean follow-up time of 12 months 
or more;
- obtained from publications within English 
dental literature;
- where patients included had been examined 
clinically at follow-up visits.
Selection of studies
Titles and abstracts of the searches were 
initially screened by two independent reviewers for 
possible inclusion in the review. The full text of all 
relevant studies was then obtained for independent 
assessment by the reviewers. Any disagreement 
was resolved by discussion. Figure 4 describes 
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were selected from an initial yield of 947 titles. 
Data were extracted using a data extraction form. 
Disagreement regarding data extraction was 
resolved by consensus, after discussions (Figure 1).
Excluded studies
Six out of 11 full-text articles examined were 
excluded from the final analysis for different 
reasons: the mean observation period was <12 
months, the type of reconstructions was not 
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osteonecrosis was an osteoradionecrosis.
Data extraction
Information on the surgical reconstructions and 
on biological complications was retrieved from the 
5 included studies. Biological complications during 
the surgery, after the surgery and in the follow-up 
period were highlighted.
RESULTS
A total of 22 patients were observed and 
treated in 5 different studies where 13 patients 
received a vascularized osteocutaneous fibula 
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completely and the postoperative course was 
uneventful with cumulative survival rate (CSR) of 
100% (Figure 6). Exceptions were represented by 
6 cases (27.27%): four patients (18.18%) had 
postoperative wound complications. The most 
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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closure; in another case (4.54%), the rupture of a 
miniplate was observed but it did not require any 
surgical exploration in a third case (4.54%), a small 
hematoma formed in the anterior portion of the 
neck incision after approximately 2 weeks from the 
operation (Figure 7). Two patients died of cancer-
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Reference Number 
of   
patients
Age of 
patients
Medical History Pharmacological therapy 
used by the patients  
Mandible 
necrosis 
involvement
Engroff and 
Kim12 2007
2 56.5 years
(mean)
2 Breast cancer 1 Pz. IV Zoledronate;
1 Pz. OS pamidronate
Partially
Ferrari, et al.15 
2008
1 66 years
old
1 Multiple myeloma 1 Pz. IV  pamidronate and later 
Zoledronate
Totally
Mucke, et al.28  
2009
1 60 years
old
1 Multiple myeloma 1 Pz. IV Zoledronate Partially
Nocini, et al.29 
2009
7 61 years
(mean)
5 Pz. Breast cancer; 1 
Pz. Prostate cancer; 
1 Pz. Multiple 
myeloma
5  Pz. IV  pamidronate and later 
Zoledronate; 
2  Pz. IV Zoledronate
2 Totally,
6 Partially
Seth, et al.43 
2010
11 61.3 years 
(mean)
5 Pz. Breast cancer; 2 
Pz. Prostate cancer;
2 Pz Multiple myeloma
2 Pz.  Osteoporosis
6 Pz. IV Zoledronate; 
2 Pz. OS Alendronate;
2 Pz. OS Ibandronate; 
1 Pz. IV Etidronate
11 Partially
Figure 5- Studies retrieved from the review of the literature: analysis of medical history, type of therapy used and mandible 
necrosis involved
Reference Number of 
patients
Type of 
study
Type of 
surgery
Type of 
technique
Cumulative 
survive rate 
of the grafts 
(CSR)
Years of 
follow-up
Engroff and Kim12 
2007
2 Case series Partial 
resection
Vascularized 

H
100% 12 
months
Ferrari, et al.15 2008 1 Case report Total resection Vascularized 

H
100% 12 
months
Mucke, et al.28 2009 1 Case report Partial 
resection
Vascularized 


osteocutaneous 
H
100% 12 
months
Nocini, et al.29 2009 7 Case series Partial 
resection
and
Total resection
Vascularized 

H
and
Vascularized 


osteocutaneous 
H
100% Range: 
6 to 34 
months
Seth, et al.43 2010 11 Case series Partial 
resection
Vascularized 


osteocutaneous 
H
100% Range: 
2 weeks 
to 31 
months
Figure 6- Studies retrieved from the review of the literature: analysis of type of surgery, type of graft used, cumulative 
survival rate of the grafts and years of follow-up
SACCO R, SACCO G, ACOCELLA A, SALE S, SACCO N, BALDONI E
related disease 8 weeks and 16 month after surgery, 
with no signs of recurrent BRONJ. BRONJ-related 
facial pain and halitosis stopped completely after 
the operation in all patients. The donor leg healed 
without complications in all cases. Stable oral lining 
and solid bone union were achieved in all patients. 
In all studies no complications were reported to the 
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rate and recurrence of the osteonecrosis were noted 
only in two cases (9.09%) (Figure 7).
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Reference Number
of   
patients
Kind of graft used Suggestions
before surgery
Postoperative 
complication
BRONJ recurrences
Engroff and 
Kim12 2007
2 2  patients were 
reconstructed with an 
FFF
ND 1 postoperative 
neck hematoma,
drained at bedside
1 patient developed 
contralateral
mandible BRONJ, 
managed 
conservatively
Ferrari, et al.15 
2008
1 1 patient were 
reconstructed with FFF
ND None None
Mucke, et al.28 
2009
1 1 patient were 
reconstructed with OFFF
ND None None
Nocini, et al.29 
2009
7 6  patients were 
reconstructed with an 
FFF and 1 with an OFFF
B therapy was 
interrupted and 25 
preoperative
sessions of (HBO)
1 Rupture of a 
miniplate
1 patient with short-
term recurrence at
resection margin, 
resolved
Seth, et al.43 
2010
11 11 patients were 
reconstructed with OFFF
ND \	

and infection, all 
reselved
None
Figure 7- >	
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postoperative wound complications and bisphosphonate-related osteonecrosis of jaws (BRONJ) recurrences
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DISCUSSION
BRONJ is a challenging complication to treat, in 
terms of both disease control and quality of life2,46, 
and its treatment is still under discussion and unclear. 
Although recommendations for the management of 
this disease exist, they are dependent on a small 
group of patients. In addition, accordance about 
prevention or conservative treatment as the basis 
for ‘‘at risk’’ patients exist18,23,25. Medical treatments 
are routinely employed together with conservative 
surgery of the exposed necrotic bone22. However, 
the initial treatment should include improvement 
of oral hygiene and systemic antibiotics to prevent 
secondary infection and pain8,14.
For the management of exposed necrotic bone, 
additional surgical debridement or sequestrectomy 
with primary mucosal closure seems to be effective 
in most cases. If there are recurrences at the 
conservative treatment, bone segment should be 
considered as it seems to be more successful than 
wound debridement alone29.
The reconstruction of subtotal mandibulectomy 
defects requires vascularized bone to promote 
healing and provide adequate soft-tissue support 
and oral competence11,45. Engroff and Kim12 (2007), 
reported two cases of microvascular reconstruction 
of the mandible in BRONJ patients. Two lateral 
mandibular defects were successfully reconstructed 

H12.
Nocini, et al.30 (2009) in their case series 
have recently shown that a properly planned 
surgical resection has high curative potential 
in BRONJ patients. Mucke, et al.29 (2009) have 
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also the vascularized iliac crest might represent 
a valuable technique. Despite the co-morbid 
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morbidity and the hospital stay, patients treated for 
osteonecrosis were comparable to that of patients 
whose mandibles are reconstructed because of 
osteoradionecrosis10,17.
Patients with reasonable life expectancy 
with regard to their malignant disease should 
be considered for microvascular tissue transfer 
after aggressive resection of the affected region. 
The quality of life can be increased and a subset 
of patients with advanced disease can be cured 
of BRONJ. As already mentioned, the basic 
pathogenesis of this disease seems to be an 
avascular osteonecrosis, particularly involving the 
jaws. It seems therefore to be possible to treat 
patients with microvascular reconstruction of the 
jaws as the transferred bone receives direct blood 
supplementation from the anastomosed artery 
(superior thyroid or facial artery). The effect of the 
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	H
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might be one of the reasons for the uneventful 
postoperative course in all patients. However, the 
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and helps establish tension free wounds in the oral 
cavity. Seth, et al.44 (2010) have shown recently 
that vascularized bone graft reconstruction with 
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high success rate with only few postoperative wound 
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complications selected patients with advanced cases 
of BRONJ.
According to literature12,15,29,30,44, radical surgical 
treatment has to be considered when:
- BRONJ seems to involve a large area of the 
jaws;
- the disease is not resolved by conservative 
therapy;
- the donor site of the patient is well perfused;
- the donor site of the patient is excluded by 
bone metastases.
However, the possibility of transferring cancer 
cells to the oral cavity during jawbone reconstruction 

H


	

	
cancer or multiple myeloma has not been observed. 
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
bone disease or multiple myeloma20. Mandibular 
reconstruction using bone-containing microvascular 
HH
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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large resection and it gives also the opportunity of 
oral prosthetic rehabilitation using dental implants, 
as described by Ferrari, et al.15 (2008) in their 
clinical report.
CONCLUSIONS
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
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of bisphosphonate therapy, and current literature 
supports only conservative defect reconstruction. 
These measures may not provide optimum 
reconstruction to achieve a well-vascularized 
healing environment, adequate oral function, and 
facial cosmetics. Microsurgical reconstruction of the 
jaws plays a critical role in improving the patient’s 
quality of life. After an observation period of 12 
months from microsurgical reconstruction of the 
jaws, high survival rates can be expected with few 
recurrences of osteonecrosis (9.09%). This, in turn, 
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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the limited number of patients found in the review 
of literature, this kind of treatment appears to be 
practicable in BRONJ-resected patients and does 
   
H   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
primary disease.
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